Market capitalization | $72.22m |
Enterprise Value | $-74.70m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.68 |
P/B ratio (TTM) P/B ratio | 0.47 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-106.96m |
Free Cash Flow (TTM) Free Cash Flow | $-109.31m |
Cash position | $171.43m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
3 Analysts have issued a HilleVax forecast:
3 Analysts have issued a HilleVax forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.20 -3.20 |
48%
48%
|
|
EBITDA | -104 -104 |
21%
21%
|
EBIT (Operating Income) EBIT | -107 -107 |
20%
20%
|
Net Profit | -147 -147 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Head office | United States |
CEO | Robert Hershberg |
Employees | 14 |
Founded | 2020 |
Website | www.hillevax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.